MYGN is expected to report earnings to fall 33.33% to -5 cents per share on July 30
Q2'26
Est.
$-0.06
Q1'26
Missed
by $0.02
Q4'25
Beat
by $0.06
Q3'25
Beat
by $0.01
Q2'25
Beat
by $0.06
The last earnings report on May 05 showed earnings per share of -9 cents, missing the estimate of -7 cents. With 1.19M shares outstanding, the current market capitalization sits at 408.96M.
A.I. Advisor
published General Information
General Information
a developer of therapeutic and predictive medicine products
A.I.dvisor indicates that over the last year, MYGN has been loosely correlated with ADPT. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if MYGN jumps, then ADPT could also see price increases.
MYGN's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for MYGN moved out of oversold territory on May 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 38 similar instances when the indicator left oversold territory. In of the 38 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on May 28, 2026. You may want to consider a long position or call options on MYGN as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MYGN just turned positive on May 27, 2026. Looking at past instances where MYGN's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for MYGN crossed bullishly above the 50-day moving average on June 12, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MYGN advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 55 cases where MYGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
MYGN moved below its 50-day moving average on June 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MYGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MYGN broke above its upper Bollinger Band on June 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MYGN entered a downward trend on May 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MYGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.212) is normal, around the industry mean (12.221). P/E Ratio (0.000) is within average values for comparable stocks, (140.227). MYGN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.506). MYGN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.008). P/S Ratio (0.487) is also within normal values, averaging (7.228).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MYGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
